Claritas Pharmaceuticals, Inc. (CLAZF)

Claritas Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Sep 30, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Net Income	-4.72	4.21	-21.21	6.94	-31.86	-11.55
Depreciation & Amortization	-	-	-	-	-	0.02
Asset Writedown & Restructuring Costs	15.63	15.63	33.77	2.61	-	-
Stock-Based Compensation	0.43	0.34	3.15	5.28	0.35	0.73
Other Operating Activities	-6.89	-14.77	-17.77	-20.85	26.65	7.55
Change in Accounts Receivable	0.06	-0.09	0.4	-0.41	-0.09	-0.02
Change in Accounts Payable	0.01	-0.48	0.36	1.18	-0.77	1.32
Change in Other Net Operating Assets	-0.6	-0.27	-0.74	0.62	0.17	0.32
Operating Cash Flow	-0.95	-0.31	-6.48	-4.85	-5.56	-1.64
Cash Acquisitions	-	-	-	-	-10	-
Other Investing Activities	-0	0	-0.01	-	-	-
Investing Cash Flow	-0	0	-0.19	-	-10	-
Long-Term Debt Issued	-	0.07	0.49	-	3.98	-
Long-Term Debt Repaid	-	-	-0.2	-	-	-
Net Debt Issued (Repaid)	0.11	0.07	0.29	-	3.98	-
Issuance of Common Stock	0.36	0.21	6.18	3.95	15.52	2.45
Repurchase of Common Stock	-	-	-	-	-	-0.31
Other Financing Activities	-	-	-	-2.56	-0.93	-0.45
Financing Cash Flow	0.47	0.28	6.48	1.39	18.57	1.69
Net Cash Flow	-0.49	-0.03	-0.2	-3.46	3.01	0.05
Free Cash Flow	-0.95	-0.31	-6.48	-4.85	-5.56	-1.64
Free Cash Flow Per Share	-0.03	-0.01	-0.29	-0.44	-0.90	-1.11
Cash Interest Paid	0.07	0.07	-	0.17	-	-
Levered Free Cash Flow	-10.71	0.27	-4.67	1.41	3.52	-4.98
Unlevered Free Cash Flow	-8.88	0.41	-4.53	1.5	3.53	-4.86
Change in Working Capital	-5.41	-5.72	-4.6	1.17	-0.69	1.61

Updated Nov 29, 2021. Source: S&P Global Market Intelligence. Standard template. Financial Sources.